In recent weeks, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.77% amid relief over the reopening of the U.S. federal government, though tempered by cooling sentiment around artificial intelligence investments. As investors navigate these shifting conditions, growth companies with high insider ownership often attract attention due to their potential for robust performance and alignment of interests between company insiders and shareholders.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 12% | 41.5% |
| MilDef Group (OM:MILDEF) | 13.7% | 83% |
| MedinCell (ENXTPA:MEDCL) | 12.5% | 96.3% |
| KebNi (OM:KEBNI B) | 36.3% | 61.2% |
| Egetis Therapeutics (OM:EGTX) | 10.3% | 86.1% |
| DNO (OB:DNO) | 13.5% | 97.5% |
| CTT Systems (OM:CTT) | 17.5% | 52% |
| Circus (XTRA:CA1) | 24.1% | 65.5% |
| CD Projekt (WSE:CDR) | 29.7% | 50.7% |
| Bonesupport Holding (OM:BONEX) | 10.4% | 49.7% |
Here we highlight a subset of our preferred stocks from the screener.
Oryzon Genomics (BME:ORY)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €238.92 million.
Operations: Oryzon Genomics S.A. generates its revenue through the discovery and development of therapeutics targeting epigenetic mechanisms for cancer and central nervous system disorders.
Insider Ownership: 15.3%
Earnings Growth Forecast: 57.1% p.a.
Oryzon Genomics showcases promising growth potential, with revenue expected to grow at 54.4% annually, outpacing the Spanish market. Despite past shareholder dilution and volatility in share price, the company is forecast to become profitable within three years. Recent earnings indicate progress with a shift from loss to net income in Q3 2025. Oryzon's innovative clinical trials for iadademstat and vafidemstat highlight its strategic focus on addressing unmet needs in sickle cell disease and CNS disorders respectively.
- Click here to discover the nuances of Oryzon Genomics with our detailed analytical future growth report.
- The analysis detailed in our Oryzon Genomics valuation report hints at an inflated share price compared to its estimated value.
P/F Bakkafrost (OB:BAKKA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: P/F Bakkafrost, along with its subsidiaries, is involved in the production and sale of salmon products across North America, Western Europe, Eastern Europe, Asia, and other international markets with a market cap of NOK27.03 billion.
Operations: The company's revenue segments include Sales and Other (DKK9.78 billion), Fishmeal, Oil and Feed (DKK2.48 billion), Farming Faroe Islands (DKK3.78 billion), Farming Scotland (DKK1.11 billion), Freshwater Faroe Islands (DKK901.81 million), Freshwater Scotland (DKK133.57 million), and Services (DKK878.36 million).
Insider Ownership: 24%
Earnings Growth Forecast: 71.2% p.a.
P/F Bakkafrost demonstrates significant growth potential, with earnings forecasted to grow over 71% annually, surpassing the Norwegian market's growth rate. Despite a recent dip in revenue and net income for the nine months ended September 2025, insider buying has been substantial, indicating confidence in future prospects. The company maintained its production guidance for 2025 and increased it for 2026 due to strong developments in the Faroe Islands and Scotland.
- Delve into the full analysis future growth report here for a deeper understanding of P/F Bakkafrost.
- The valuation report we've compiled suggests that P/F Bakkafrost's current price could be quite moderate.
Vimian Group (OM:VIMIAN)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Vimian Group AB (publ) operates in the animal health sector globally, with a market capitalization of approximately SEK15.40 billion.
Operations: Vimian Group AB's revenue is derived from four main segments: Medtech (€153.80 million), Diagnostics (€22.70 million), Specialty Pharma (€181.60 million), and Veterinary Services (€63.10 million).
Insider Ownership: 12.7%
Earnings Growth Forecast: 39.1% p.a.
Vimian Group is positioned for substantial growth, with earnings anticipated to increase significantly over the next three years, outpacing Swedish market averages. The company has seen strong insider buying recently, reflecting confidence in its strategic direction. Despite a forecasted revenue growth rate below 20% annually, Vimian's robust M&A strategy aims to drive expansion in the global animal health sector. Recent financial results show improved profitability and sales performance compared to last year.
- Click here and access our complete growth analysis report to understand the dynamics of Vimian Group.
- Insights from our recent valuation report point to the potential undervaluation of Vimian Group shares in the market.
Make It Happen
- Access the full spectrum of 199 Fast Growing European Companies With High Insider Ownership by clicking on this link.
- Curious About Other Options? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 38 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Oryzon Genomics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com